Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review

Abstract Background The administration of second-line or subsequent immune checkpoint inhibitors (ICIs) in previously treated patients with advanced solid cancers has been clinically investigated. However, previous clinical trials lacked an appropriate primary endpoint for efficacy assessment. This...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Jingqiu Li, Xiaoding Zhou, Lei Wu, Jiabao Ma, Yan Tan, Songke Wu, Jie Zhu, Qifeng Wang, Qiuling Shi
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2025-02-01
Σειρά:	BMC Cancer
Θέματα:	Early efficacy endpoint Immune checkpoint inhibitor Advanced solid cancer Progression-free survival Objective response Overall survival
Διαθέσιμο Online:	https://doi.org/10.1186/s12885-025-13712-0
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!